Innovent's phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 market

Innovent Biologics is ready to make its play for the Chinese PCSK9 inhibitor market. Having racked up another two phase 3 wins, Innovent is preparing to file for an approval that would position it as a rival to Amgen’s Repatha and Sanofi’s Praluent in China.